DE69017302T2 - Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. - Google Patents

Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.

Info

Publication number
DE69017302T2
DE69017302T2 DE69017302T DE69017302T DE69017302T2 DE 69017302 T2 DE69017302 T2 DE 69017302T2 DE 69017302 T DE69017302 T DE 69017302T DE 69017302 T DE69017302 T DE 69017302T DE 69017302 T2 DE69017302 T2 DE 69017302T2
Authority
DE
Germany
Prior art keywords
treatment
psychiatric diseases
cholecystokinin antagonists
central
central cholecystokinin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69017302T
Other languages
English (en)
Other versions
DE69017302D1 (de
DE69017302T3 (de
Inventor
David Christopher Horwell
John Hughes
Geoff Neil Woodruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27012795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69017302(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of DE69017302D1 publication Critical patent/DE69017302D1/de
Publication of DE69017302T2 publication Critical patent/DE69017302T2/de
Application granted granted Critical
Publication of DE69017302T3 publication Critical patent/DE69017302T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69017302T 1989-08-04 1990-08-03 Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. Expired - Fee Related DE69017302T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38966589A 1989-08-04 1989-08-04
US42189689A 1989-10-16 1989-10-16

Publications (3)

Publication Number Publication Date
DE69017302D1 DE69017302D1 (de) 1995-04-06
DE69017302T2 true DE69017302T2 (de) 1995-09-28
DE69017302T3 DE69017302T3 (de) 1999-08-05

Family

ID=27012795

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69017302T Expired - Fee Related DE69017302T3 (de) 1989-08-04 1990-08-03 Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.

Country Status (9)

Country Link
US (1) US5550126A (de)
EP (2) EP0727215A3 (de)
JP (1) JPH0374328A (de)
AT (1) ATE119040T1 (de)
CY (1) CY1983A (de)
DE (1) DE69017302T3 (de)
DK (1) DK0411668T4 (de)
HK (1) HK8197A (de)
LV (1) LV11431B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69017302T3 (de) * 1989-08-04 1999-08-05 Merck Sharp & Dohme Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
US5324726A (en) * 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5399565A (en) * 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
US5206238A (en) * 1990-11-13 1993-04-27 Merck & Co., Inc. Cholecystokinin antagonists
US5218115A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5220018A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5185331A (en) * 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
EP0518484A3 (en) * 1991-05-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders
US5206237A (en) * 1991-05-14 1993-04-27 Merck & Co., Inc. Benzodiazepine analogs
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
EP0517412A1 (de) * 1991-06-03 1992-12-09 MERCK SHARP & DOHME LTD. Pharmazeutische Zusammensetzungen enthaltend eine Benzodiazepen
US5177071A (en) * 1991-06-17 1993-01-05 Merck & Co., Inc. 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
US5153191A (en) * 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
WO1993012791A1 (en) * 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
IT1263116B (it) * 1992-04-09 1996-07-30 Rotta Research Lab Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
EP0591550B1 (de) * 1992-04-22 1998-03-18 Copal Company Limited Absolute kodiereinrichtung
US5360802A (en) * 1992-05-11 1994-11-01 Merck Sharpe & Dohme Ltd. Benzodiazepine derivatives, compositions containing them and their use in therapy
US5378838A (en) * 1993-01-13 1995-01-03 Merck & Co., Inc. Benzodiazepine cholecystokinin antagonists
US5852010A (en) * 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5929071A (en) * 1996-07-02 1999-07-27 Merck & Co., Inc. Method for the treatment of preterm labor
WO1998000406A1 (en) * 1996-07-02 1998-01-08 Merck & Co., Inc. Method for the treatment of preterm labor
WO1999008667A2 (en) * 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
IL142816A0 (en) * 1998-12-24 2002-03-10 Du Pont Pharm Co SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
EP1183242A2 (de) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company Als hemmer der reversen transcriptase von hiv verwendbare 1,4-benzodiazepin-2-one
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1222176A1 (de) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company Amino-laktam-sulfonamide als inhibitoren der bildung von a-beta-protein
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
CN1436175A (zh) * 2000-04-03 2003-08-13 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ－蛋白生产抑制剂的环状内酰胺
EP1289966A1 (de) 2000-04-11 2003-03-12 Bristol-Myers Squibb Pharma Company Lactamderivate als inhibitoren von a beta protein-produktion
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
AU2001261728A1 (en) * 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US20040167146A1 (en) * 2002-01-22 2004-08-26 Karen Jackson Method of treatment
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment
US20030139396A1 (en) * 2002-01-22 2003-07-24 Karen Gibson Method of treatment
US20040043990A1 (en) * 2002-04-09 2004-03-04 Karen Jackson Method of treatment
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
PL2081921T3 (pl) 2006-07-10 2011-03-31 Paion Uk Ltd Krótko działające sole benzodiazepiny i ich formy polimorficzne
CA2685860A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2450039A1 (de) 2010-11-08 2012-05-09 PAION UK Ltd. Dosierschema zur Sedierung mit CNS 7056 (Remimazolam)
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (de) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomainhemmer und ihre verwendungen
EP2864336B1 (de) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazolazepinbromdomänenhemmer und verwendungen davon
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
PL3071206T3 (pl) 2013-11-22 2022-01-17 CL BioSciences LLC Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212436A (en) * 1984-06-25 1989-04-26 Rotta Research Lab D,l-glutamic and d,l-aspartic acid derivatives and pharmaceutical compositions
US5004741A (en) * 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
CA1332410C (en) * 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
IT1215169B (it) * 1985-12-17 1990-01-31 Rotta Research Lab Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
IT1217123B (it) * 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
DE69017302T3 (de) * 1989-08-04 1999-08-05 Merck Sharp & Dohme Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
US5153191A (en) * 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression

Also Published As

Publication number Publication date
EP0411668A3 (en) 1992-01-29
ATE119040T1 (de) 1995-03-15
DE69017302D1 (de) 1995-04-06
DK0411668T4 (da) 1999-08-09
HK8197A (en) 1997-01-24
EP0727215A3 (de) 1996-11-06
CY1983A (en) 1997-09-05
US5550126A (en) 1996-08-27
LV11431A (lv) 1996-08-20
EP0411668A2 (de) 1991-02-06
DK0411668T3 (da) 1995-03-27
EP0411668B2 (de) 1998-11-11
LV11431B (en) 1996-12-20
EP0727215A2 (de) 1996-08-21
DE69017302T3 (de) 1999-08-05
JPH0374328A (ja) 1991-03-28
EP0411668B1 (de) 1995-03-01

Similar Documents

Publication Publication Date Title
DE69017302T3 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
ATE398618T1 (de) Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
ATE127804T1 (de) Pharmazeutische verbindungen.
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
ES2147616T3 (es) Derivados de piperidina con actividad antagonista del paf.
ATE205480T1 (de) 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE3887068D1 (de) 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
ES2062145T3 (es) 1,8-naftiridinas substituidas.
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
DE3850044D1 (de) Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
BR9810331A (pt) Sal de adição de ácido maléico de 2-etil-5-(1-metil-1,2,5,6-tetraidro-3-piridil-2h-tetrazol ; composições farmacêuticas contendo o referido sal; método para sua preparação e a utilização do mesmo em tratamento de doenças
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.
IT8920006A0 (it) Composizioni farmaceutiche comprendenti derivati del glicerolo 3 fosfato atte al trattamento di patologie del sistema nervoso
IT9019882A0 (it) Composizioni farmaceutiche comprendenti derivati del glicerolo-5- fosfato atte al trattamento di patologie del sistema nervoso

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de
8339 Ceased/non-payment of the annual fee